By Brendan Pierson (Reuters) - Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging "exorbitant" prices for its blockbuster hepatitis C drug Sovaldi. The lawsuit, filed Tuesday in federal court in Philadelphia by the Southeastern Pennsylvania Transportation Authority, seeks an unspecified amount of money damages. Sovaldi, a highly effective treatment for hepatitis C, costs $1,000 per pill in the United States, or $84,000 for a typical 12-week course. The drug sells for much less in some other countries. ...
via Health News Headlines - Yahoo News http://ift.tt/12vE0Co
via Health News Headlines - Yahoo News http://ift.tt/12vE0Co
No comments:
Post a Comment